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mated to currently suffer from OAB across the ﬁve countries. An
estimated 2.5m also have symptoms of urge incontinence. By
2020, 2.1m additional males are expected to be affected by
OAB. The average health care cost associated with managing
these patients ranged from €200 in the UK to €732 in Italy. The
total cost of OAB in males aged >40 were estimated to be €1.7
billion in 2005: €412m in Germany; €607m in Italy; €350 in
Spain; €71m in Sweden and €231 in the UK. By 2020, the total
cost of OAB in males is expected to increase to €2 billion. This
compares with a total burden of €4.1 billion in 2005 and pro-
jected total burden of €5.2 billion in 2020. DISCUSSION: The
burden of OAB in males was 40% of the total burden in the
overall population aged > 40. The economic burden is likely 
to increase in line with our prevalence forecasts. Since many
males do not seek treatment, the future cost burden may be
underestimated.
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CHARACTERISTICS RELATED TO PRODUCTIVITY LOSS IN
PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM THE
MATRIX STUDY
Pizzi LT1, Gemmen E2, Dahl NV3
1Jefferson Medical College, Philadelphia, PA, USA; 2Quintiles, Falls
Church,VA, USA; 3Watson Laboratories, Morristown, NJ, USA
OBJECTIVE: To determine characteristics related to lost pro-
ductivity in working adults with overactive bladder (OAB) using
data from a large US multicenter trial. METHODS: Baseline data
were obtained from 2770 participants in the Multicenter Assess-
ment of Transdermal Therapy in Overactive Bladder with Oxy-
butynin (MATRIX). Productivity was assessed using the Work
Productivity Questionnaire (WPQ), a modiﬁed version of the
Work Limitations Questionnaire (WLQ) which captures physi-
cal, mental (concentration), time (interruptions and adherence to
a schedule), and output (ability to handle workload) domains
related to work productivity. Additional questions on demo-
graphics, prior OAB treatment, and daily pad use were asked. A
WPQ Index was computed to estimate productivity impairment
compared to healthy individuals. Characteristics related to pro-
ductivity loss were determined using group comparisons (t-test).
RESULTS: Approximately half (52.7%) of participants were of
working age (18–64 years), and 44.9% were employed. The
majority were female (92.0%) and white (81.2%). Overall,
working participants were approximately 7.9% less productive
than healthy individuals. Group comparisons revealed that
females experienced greater physical limitations than males (p <
0.05) but had similar time, mental, and output scores. Age
younger than 65 was associated with greater impairments of
time, mental, and output domains (p < 0.05 for all). Minorities
(African Americans, Hispanics, and Asians) experienced signiﬁ-
cantly less productivity than whites across all categories with the
exception that African Americans reported similar time impair-
ments to whites. Productivity scores were inversely related to
daily pad use (those using 1- or 2- experiencing higher scores
than those using 3 or more), and did not differ between treat-
ment naïve and those previously treated (p > 0.05 for all
domains). CONCLUSIONS: OAB causes job interruptions, dif-
ﬁculties in adhering to a schedule, physical limitations, impaired
concentration, and reduced ability to handle workload. Females
with OAB experience more physical limitations than males, and
minorities generally experience greater productivity impairments
than whites.
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IDENTIFYING PREDICTORS OF OFF-LABEL UTILIZATION
PATTERNS OF TWO BIOTECHNOLOGY DRUGS,
RECOMBINANT ERYTHROPOIETIN ALFA AND DARBEPOETIN
ALFA: A MULTI-HOSPITAL STUDY
Patkar AD, Holdford DA, Peterson SP
Virginia Commonwealth University, Richmond,VA, USA
OBJECTIVES: To identify predictors of off-label utilization of
Erythropoietin and Darbepoetin across hospitals in the United
States. METHODS: A retrospective database (Solucient®) review
was performed on 169,288 discharged patients who received ery-
thropoietin and darbepoetin across 187 hospitals. Based upon
an evidence-based medicine framework, utilization of the two
drugs was categorized as “on-label” (approved by the FDA),
“off-label-supported” (not FDA-approved but with strong evi-
dence supporting off-label use), and “off-label-unsupported”
(minimal literature support for off-label indications). A multin-
omial logistic regression model clustered by hospitals was used.
Model covariates were patient demographics, clinical outcomes,
physician specialty, hospital size, teaching status, region, drug
dose, and number of administrations. RESULTS: Relative to on-
label, physician specialty, patient age group, race, and drug cov-
erage were signiﬁcant (at the 0.05 level) predictors of off-label
use (supported and unsupported). Surgeons were twice as likely
to prescribe off-label-unsupported (OFUS) than generalists 
and four times more likely than specialists. Infants (0–1 years),
{RRR-164; 95%CI, 84–319}, children (1–17 years), {RRR-2.30;
95%CI, 1.45–5.0}, and young-adults (18–24 years) {RRR-2.30,
95%CI, 2.07–3.19} were more likely to receive OFUS compared
to middle-aged adults (40–59 years), while OFUS prescribing 
for individuals over 75 years was weakly predictive (RRR-1.28;
95%CI, 1.03–1.6). African-Americans and Native-Americans
were twice as likely to receive drugs for off-label-supported
(OFS) but half as likely for OFUS use relative to whites. More-
over, Title-V, Worker’s compensation, and self-pay patients were
more likely to receive OFUS. CONCLUSIONS: Variations in off-
label prescribing among physician specialties may reﬂect a lack
of consensus on practice guidelines. The common use of OFUS
prescribing in pediatrics may be explained by the limited clini-
cal trial data on children. Racial differences in OFUS may indi-
cate differing disease prevalence in populations. Knowing causes
of off-label prescribing can help decision makers understand the
degree to which it is appropriate.
HP2
PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG
THERAPY ALERTS IN A LONG TERM CARE SETTING
Wegner S1,Trygstad T2, Christensen DB2
1AccessCare, Inc, Morrisville, NC, USA; 2University of North Carolina,
Chapel Hill, NC, USA
OBJECTIVES: We implemented a focused drug therapy man-
agement intervention aimed at reducing polypharmacy for Med-
icaid recipients in North Carolina nursing homes. Targeted were
patients receiving >18 prescriptions in 90 days. During sched-
uled monthly home visits, consultant pharmacists providing
routine drug regimen reviews also reviewed drug proﬁles dis-
playing claims-generated drug problem alerts. Pharmacists doc-
umented reviews, recommendations and resulting drug therapy
changes. Study objectives were to determine: 1) the frequency
with which potential drug therapy problems (PDTPs) were found
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and persisted following interventions, and 2) the impact of inter-
ventions on quality, and patient drug costs from a payer per-
spective. METHODS: Before-after study with comparison group
design. Medicaid prescription claims data were compared for
three months prior to and following the intervention. RESULTS:
In total, 253 nursing homes, 110 consultant pharmacists, and
6344 patients participated in the study arm, with 5160 patients
remaining at the end of the follow-up period. At baseline, study
group patients used an average of 9.7 prescriptions per month,
costing the NC Medicaid program $517(USD). There were 5918
recommendations offered for 3262 patients, or an average of
1.58 per patient. At least one proﬁle-related pharmacist inter-
vention was implemented for 72% of patients, about half involv-
ing a switch to a lower cost drug. Two of ﬁve alert categories
had highly signiﬁcant reductions in alert persistence of 10.8%
and 29.7% respectively versus 0.7% and 14.1% in the compar-
ison group. Drug costs for study group patients were $57 
lower than comparison group patients at follow-up (p < 0.05).
CONCLUSIONS: A supplemental program of medication
reviews for targeted NH patients resulted in a reduction in the
persistence of PDTP alerts and was cost beneﬁcial based solely
on drug cost savings. This intervention may be a model for future
medication therapy management services provided by prescrip-
tion drug plans under Medicare for patients in long-term-
care settings.
HP3
PHYSICIAN PRESCRIBING OF SLEEP DISORDER
MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS:
FACTORS AFFECTING PRESCRIPTION OF HIGH ABUSE
POTENTIAL AND COSTLY MEDICATIONS
Rasu R1, Balkrishnan R2, Shenolikar R2, Nahata M2
1University of Missouri Kansas City, Kansas City, MO, USA; 2Ohio
State University College of Pharmacy, Columbus, OH, USA
OBJECTIVE: This research was performed to analyze selected
socioeconomic and clinical factors relating to both physicians
and patients associated with physicians’ prescribing of expensive
medications and medications with abuse potential side effects 
for treatment of sleep difﬁculties in a nationally representative
sample of outpatient physician visits in the United States.
METHODS: A multivariate logistic regression method was used
to analyze the 1996–2001 National Ambulatory Medical Care
Survey data to determine the patient and physician factors asso-
ciated with a prescription for expensive medication and medica-
tions with abuse potential side effects in outpatient settings.
RESULTS: From 1996 to 2001, about 94.6 million sleep-
difﬁculty related visits were made to outpatient physician ofﬁces
in the United States. Forty eight percent (45 million) of sleep-
difﬁculty related visits received prescription for medication
therapy only. Patients over 65 years of age were 44% less likely
(OR: 0.56, 95% CI: 0.35–0.90) to receive an expensive medica-
tion prescriptions than patients aged 18–34 years (reference
group). Hispanic patients were 56% less likely to receive an
expensive medication prescription than Non-Hispanic patients
during their visits (OR: 0.44, 95% CI: 0.22–0.88). Male patient
visits were 39% less likely than female patient visits to result in
receipt of medication with abuse potential among patient visits
receiving medication therapy (OR: 0.61, 95% CI: 0.45–0.81). In
addition, patients with mental co-morbidities were 80% more
likely to be associated with receipt of a prescription of medica-
tions with abuse potential than patients with no mental co-
morbidities (OR: 1.80, 95% CI: 1.31–2.47). CONCLUSIONS:
This study indicated that patient’s age and ethnicity inﬂuence
physician prescribing of expensive medications for treatment of
sleep difﬁculties. In addition, increased probability of receipt of
medication with abuse potentials in female gender is of concern,
when safer alternative medications with lower abuse potentials
are easily available.
HP4
PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY—
WHAT DO THE PATIENTS WANT?
Kielhorn H1,Wolter AB1, Schoenermark MP2
1Schoenermark, Kielhorn and Collegen, Hannover, Germany;
2Hannover Medical School, Hannover, Germany
OBJECTIVES: To understand and quantify the consumers’
choice and preferences for the heavily discussed and politically
promoted introduction of gatekeeper models in primary care as
a measure of effective cost containment. Furthermore, to explore
which of the patients’ segments could be addressed by which
value proposition, which design elements to use and what kind
of incentive structures to create. METHODS: Applying stochas-
tic methods, a representative sample of 3024 people from the
health insured population was taken and segmented according
to four basic dimensions (age, gender, income, and insurance
status). About 1000 interviews were performed in a telephone
survey. Participants were asked 10 questions about their knowl-
edge on primary care and gatekeeper models. Other questions
addressed aspects such as design elements of potential gatekeeper
models, parameters for the interviewee’s choice on a potential
family doctor, demands on the quality of a family doctor, and
incentive structures. RESULTS: The participants showed differ-
entiated answer proﬁles. Older and currently ill people were 
signiﬁcantly better informed concerning gate keeper models in
primary care. In total, 88% already go to their family doctor and
60% use their family doctor as the primary address and would
participate at a gatekeeper model without extra incentives. The
demands on family doctors are dependent on age and gender.
Neighbourhood and personal experience as well as quality and
service level are key factors. CONCLUSIONS: It can be con-
cluded that even without being well informed and without
explicit incentive structures, the insured already behave accord-
ing to the principles of primary care and gatekeeper models, 
limiting the political effect of reorganising patient streams 
in ambulatory care. Furthermore, insurance companies should
investigate consumers’ choices in primary care before setting up
sophisticated incentive systems.
Methods and Concepts in Patient-Oriented Research
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TRAJECTORIES OF EQ-5D QUALITY OF LIFE UTILITY SCORES
FOR 10,000 SCHIZOPHRENIA OUTPATIENTS OVER 2 YEARS: A
REPORT FROM THE SOHO STUDY
Hammond GC1, Croudace TJ1, Jones PB1, Belger M2, Novick D2
1University of Cambridge, Cambridge, UK; 2Eli Lilly and Company Ltd,
Windlesham, Surrey, UK
OBJECTIVES: Extensive longitudinal data are required to char-
acterize the outcomes of serious mental disorders. Statistical
methods for proﬁling individual differences in clinical and social
outcomes, and the impact of treatment have expanded over the
past decade, are now implemented in user friendly software. Our
aim was to characterize individual trajectories in patient-rated
quality of life scores recorded over two years. METHODS: The
sample comprised 10,000 outpatients with schizophrenia partic-
ipating in the Schizophrenia Outpatient Health Outcomes
(SOHO) observational study of health outcomes of antipsychotic
treatment which was conducted in 10 European countries.
SOHO enrolled schizophrenia outpatients who were initiating 
or changing their antipsychotic medication. The outcome was
